This week, members of our leadership team will participate in a fireside chat at the @BofA_Business Securities Health Care Conference, where they’ll discuss our corporate growth strategy. Register for the webcast: bofa.veracast.com/webcasts/b… #PoweringWhatsPossible

Today, we’re sharing our first quarter 2026 financial results including the continued progress on our corporate growth strategy. Join our live call at 8:30 a.m. ET: app.webinar.net/dMQ1j57YqOv Read the full press release: ir.novavax.com/press-release… #Earnings #FinancialResults

Join us Wednesday, May 6 as we report our first quarter financial results for 2026 and share key operational highlights. Get the details and register here:  ow.ly/MIMC50YS2yH #Earnings #FinancialResults

Today, we’re sharing our Q4 and FY 2025 financial results and the continued progress on our corporate strategy. Join our live call starting at 8:30 a.m. E.T. here: app.webinar.net/RO3Y2A8EZqP Full press release: ir.novavax.com/press-release…

Join us next Thursday, February 26 as we report our fourth quarter and full year 2025 financial results and share key operational highlights. More information: lnkd.in/eBfDQYBj #Earnings #FinancialResults

#NEWS: Novavax has entered into a non-exclusive license agreement with @pfizer for use of Novavax’s Matrix-M® adjuvant for up to two disease areas. This new partnership shows our corporate strategy in action, and adds to the successful collaboration we have with Sanofi, among other major companies. We’re excited to be executing on our strategy to drive incremental value from partnerships and R&D innovation, with the potential to create new or improve existing products using Novavax’s differentiated technology platform. Ultimately, these partnerships increase access for the people who could benefit from products built with our technology and importantly drive incremental value for investors and for global public health. Visit ir.novavax.com/ to get details on the potential value we are building with this partnership, including $30 million upfront, up to $500 million in milestone payments and more. We’re excited to work with you, Pfizer. Read more: ir.novavax.com/press-release…

We’re looking forward to attending this year’s @jpmorgan Healthcare Conference. Learn more: ir.novavax.com/press-release…

#NEWS: Novavax completes U.S. marketing authorization transfer to @Sanofi for Nuvaxovid™, following the EU transfer in October in line with its collaboration and license agreement as well as its corporate strategy. ow.ly/tbUY50XmnVO

#NEWS: Novavax executes planned site consolidation, further reducing cost footprint in line with our corporate strategy. Learn more: ir.novavax.com/press-release…

This #HealthLiteracyMonth, we’re sharing accessible information on vaccines to empower people to make informed health decisions. Building #HealthLiteracy is essential to address uncertainties, strengthen confidence and ultimately improve global health. Watch to learn more.

#NEWS: Novavax continues to deliver on @Sanofi partnership, completing Nuvaxovid® EU marketing authorization transfer. ir.novavax.com/press-release…

Novavax has further deepened its partnership with Sanofi, announcing an expansion of Sanofi’s license to include the use of Matrix-M® adjuvant in Sanofi’s pandemic influenza vaccine candidate program, supported by recent BARDA funding. Read more: ir.novavax.com/press-release…

#NEWS: Our COVID-19 vaccine is now approved in Japan for individuals aged 6 and older. Learn more: ir.novavax.com/press-release…

The 2025-2026 formulation of our COVID-19 vaccine is approved for use in individuals 65 years and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. ir.novavax.com/press-release…

#NEWS: Novavax announced the U.S. Food and Drug Administration (@FDA) has approved the Company’s Biologics License Application for its COVID-19 vaccine, Nuvaxovid™, triggering a Sanofi milestone payment. Read the news release: ir.novavax.com/press-release…

#Statement: Novavax responded to the formal communication request for a postmarketing commitment received from the U.S. Food and Drug Administration (FDA) for our Biologics License Application (BLA). Read more: ir.novavax.com/press-release…

#Statement: We have received formal communication from the U.S. Food and Drug Administration (FDA) about the Novavax COVID-19 vaccine Biologics License Application (BLA). Read more: ir.novavax.com/press-release…

At this year’s #ESCMID Congress, we presented new real-world data from the SHIELD-Utah study conducted in partnership with the University of Utah Health Read more about the findings: ir.novavax.com/press-release…

An update on the status of Novavax’s COVID-19 Vaccine BLA